177 related articles for article (PubMed ID: 16009063)
1. The effectiveness of highly active antiretroviral therapy in HIV-infected patients.
Jensen-Fangel S
Dan Med Bull; 2004 Nov; 51(4):371-92. PubMed ID: 16009063
[No Abstract] [Full Text] [Related]
2. Substitution for protease inhibitors in HIV therapy.
Mikhail E
N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14689602
[No Abstract] [Full Text] [Related]
3. Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption.
Barreiro P; de Mendoza C; González-Lahoz J; Soriano V
Clin Infect Dis; 2005 Sep; 41(6):897-900. PubMed ID: 16107992
[TBL] [Abstract][Full Text] [Related]
4. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
Ananworanich J; Hirschel B; Sirivichayakul S; Ubolyam S; Jupimai T; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Schutz M; Snowden W; Ruxrungtham K;
Antivir Ther; 2006; 11(5):631-5. PubMed ID: 16964832
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
[TBL] [Abstract][Full Text] [Related]
6. Antimalarial activity of sera from subjects taking HIV protease inhibitors.
Redmond AM; Skinner-Adams T; Andrews KT; Gardiner DL; Ray J; Kelly M; McCarthy JS
AIDS; 2007 Mar; 21(6):763-5. PubMed ID: 17413699
[TBL] [Abstract][Full Text] [Related]
7. Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.
Martínez E; Gatell JM
AIDS; 2007 Aug; 21(13):1829-30. PubMed ID: 17690588
[No Abstract] [Full Text] [Related]
8. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
[TBL] [Abstract][Full Text] [Related]
9. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
[TBL] [Abstract][Full Text] [Related]
10. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004.
Lohse N; Obel N; Kronborg G; Jørgensen LB; Pedersen C; Larsen CS; Kvinesdal B; Sørensen HT; Gerstoft J
Antivir Ther; 2006; 11(5):591-600. PubMed ID: 16964827
[TBL] [Abstract][Full Text] [Related]
11. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F
AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351
[TBL] [Abstract][Full Text] [Related]
12. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
14. Saquinavir, the pioneer antiretroviral protease inhibitor.
la Porte CJ
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1313-22. PubMed ID: 19737048
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark.
Bracher L; Valerius NH; Rosenfeldt V; Herlin T; Fisker N; Nielsen H; Obel N
Scand J Infect Dis; 2007; 39(9):799-804. PubMed ID: 17701719
[TBL] [Abstract][Full Text] [Related]
16. Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children.
Pensieroso S; Romiti ML; Palma P; Castelli-Gattinara G; Bernardi S; Freda E; Rossi P; Cancrini C
AIDS; 2006 Sep; 20(14):1893-6. PubMed ID: 16954733
[TBL] [Abstract][Full Text] [Related]
17. Anti-HIV agents. Saquinavir--switching from Fortovase to Invirase.
TreatmentUpdate; 2004; 16(3):8-9. PubMed ID: 17219608
[No Abstract] [Full Text] [Related]
18. Effectiveness and durability of non-nucleoside reverse transcriptase inhibitor-based therapy in HIV clinical practice.
Kan VL
AIDS; 2007 Apr; 21(7):880-2. PubMed ID: 17415048
[No Abstract] [Full Text] [Related]
19. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
Müller AD; Myer L; Jaspan H
Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495
[TBL] [Abstract][Full Text] [Related]
20. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]